Jie Jin
First Affiliated Hospital of Zhejiang University · Zhejiang University · The first affiliated hospital, Zhejiang Unviersity school of medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jie Jin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:37 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07925190 · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsBeijing InnoCare Pharma Tech Co., Ltd. · not yet recruiting · Acute Myeloblastic Leukaemia · principal investigator
- Ph1/Ph2NCT07102706 · Phase I Trial of GR1803 Injection in Patients With RRMMGenrix (Shanghai) Biopharmaceutical Co., Ltd. · completed · Multiple Myeloma (MM) · principal investigator
- Ph2NCT06754267 · Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLFirst Affiliated Hospital of Zhejiang University · recruiting · Precursor B-Cell Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT06705725 · Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple MyelomaCarbiogene Therapeutics Co. Ltd. · not yet recruiting · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT06580301 · Study of YK012 in B-cell Acute Lymphoblastic LeukemiaExcyte Biopharma Ltd · recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT06566547 · GR1803 Injection in Patients With Relapsed/Refractory Multiple MyelomaGenrix (Shanghai) Biopharmaceutical Co., Ltd. · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT06511869 · AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)Dizal Pharmaceuticals · completed · Peripheral T-cell Lymphoma · principal investigator
- Ph2NCT06434662 · Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AMLFirst Affiliated Hospital of Zhejiang University · unknown · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy · principal investigator
- Ph3NCT06389292 · A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaAscentage Pharma Group Inc. · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT05650580 · TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid TumorsTarapeutics Science Inc. · unknown · Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT05611853 · Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesBioNova Pharmaceuticals (Shanghai) LTD. · terminated · B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma · principal investigator
- Ph3NCT05586074 · HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLSunshine Lake Pharma Co., Ltd. · recruiting · Leukemia, Acute Myeloid (AML) · principal investigator
- Ph1/Ph2NCT05565807 · Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaZhejiang ACEA Pharmaceutical Co. Ltd. · recruiting · Relapsed or Refractory Multiple Myeloma · principal investigator
- Ph3NCT05236621 · A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaQilu Pharmaceutical Co., Ltd. · unknown · Multiple Myeloma, Recurrent or Refractory · principal investigator
- Ph1/Ph2NCT05133882 · A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AMLSunshine Lake Pharma Co., Ltd. · recruiting · Acute Myeloid Leukemia, Adult · study chair
- Ph2NCT04851535 · Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.Suzhou Zelgen Biopharmaceuticals Co.,Ltd · completed · Myelofibrosis · principal investigator
- Ph1NCT04827069 · A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)Sunshine Lake Pharma Co., Ltd. · completed · Acute Myeloid Leukemia · study chair
- Ph1NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaFirst Affiliated Hospital of Zhejiang University · unknown · Non-Hodgkin's B-cell Lymphoma · principal investigator
- Ph1NCT04689308 · This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell MalignanciesMinghui Pharmaceutical (Shanghai) LTD · unknown · Relapsed/Refractory B-cell Malignancies · principal investigator
- Ph4NCT04645550 · Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT)Northern Jiangsu People's Hospital · completed · Cirrhosis, Splenectomy; Status, Venous Thrombosis · principal investigator
- Ph3NCT04617028 · Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk MyelofibrosisSuzhou Zelgen Biopharmaceuticals Co.,Ltd · completed · Myelofibrosis · principal investigator
- Ph1/Ph2NCT04501120 · Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLAscentage Pharma Group Inc. · recruiting · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy · principal investigator
- Ph2NCT04217993 · Jaktinib for the Treatment of Ruxolitinib Intolerance of MyelofibrosisSuzhou Zelgen Biopharmaceuticals Co.,Ltd · completed · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF) · principal investigator
- Ph1/Ph2NCT03994913 · Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell LymphomaCARsgen Therapeutics Co., Ltd. · completed · Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT03886415 · Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.Suzhou Zelgen Biopharmaceuticals Co.,Ltd · completed · Myelofibrosis · study chair
- Ph1NCT03716856 · Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaFirst Affiliated Hospital of Zhejiang University · unknown · Refractory or Relapsed Multiple Myeloma · principal investigator
- Ph3NCT03591406 · To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency AnaemiaVifor (International) Inc. · completed · Iron Deficiency Anemia · principal investigator
- Ph1NCT03588598 · Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesNanjing Sanhome Pharmaceutical, Co., Ltd. · unknown · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL) · principal investigator
- Ph1NCT03060850 · A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLHangzhou ACEA Pharmaceutical Research Co., Ltd. · unknown · B-cell Lymphoma · principal investigator
- N/ANCT02961413 · A Prospective Cohort Study on Drug-induced Liver Injury in China(DILI-P)Drug Induced Liver Disease Study Group · recruiting · Drug-induced Liver Injury · principal investigator
- Ph4NCT02247414 · Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal DisconnectionYangzhou University · completed · Cirrhosis, Hypertension, Status;Splenectomy · principal investigator
- Ph4NCT02238444 · Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic SplenectomyYangzhou University · unknown · Cirrhosis, Hypertension, Venous Thrombosis · principal investigator
- Ph3NCT01786473 · Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male HypogonadismLaboratoires Besins International · unknown · Hypogonadism · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 12:37 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.J Clin Oncol · 2020378 citationsRCR 15.0
- In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells.Blood · 199550 citationsRCR 1.2